GlassScriptPhysician profile
John Paul Bunka
NPI 1457611956
$24,843.09
in general payments reported to CMS, 2019-2025
18 companies · $9,965 in 2025
The $9,965 reported for 2025 was more than what 89% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $640 · 2020: $432 · 2021: $491 · 2023: $4,628 · 2024: $8,687 · 2025: $9,965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Consulting Fee: $2,862 · Food and Beverage: $1,805 · Travel and Lodging: $1,477 · Education: $8.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,127.00 |
| Consulting Fee | $2,862.00 |
| Food and Beverage | $1,805.04 |
| Travel and Lodging | $1,477.37 |
| Education | $8.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $22,684.29 | 2020-2025 | Valtoco |
| Supernus Pharmaceuticals, INC. | $782.67 | 2019-2021 | |
| Eisai INC. | $344.33 | 2019-2025 | |
| Sk Life Science, INC. | $315.78 | 2021-2025 | |
| Neuropace, INC. | $125.66 | 2021-2023 | |
| Jazz Pharmaceuticals INC. | $107.42 | 2023 | |
| Janssen Pharmaceuticals, INC | $99.00 | 2021 | |
| Amgen INC. | $81.30 | 2019-2021 | |
| Greenwich Biosciences, INC. | $57.39 | 2019 | |
| Ucb, INC. | $54.04 | 2020-2024 | Fintepla |
| Genzyme Corporation | $41.42 | 2019 | |
| Abbvie INC. | $35.06 | 2025 | |
| Aucta Pharmaceuticals, INC. | $26.98 | 2024 | Motpoly Xr |
| Dynasplint Systems INC. | $25.34 | 2025 | Dynasplint |
| Tg Therapeutics, INC. | $21.26 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $16.70 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $13.40 | 2021 | |
| Kyowa Kirin, INC. | $11.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bunka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.